TY - JOUR
T1 - Global cardiovascular and renal outcomes of reduced GFR
AU - On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group
AU - Thomas, Bernadette
AU - Matsushita, Kunihiro
AU - Abate, Kalkidan Hassen
AU - Al-Aly, Ziyad
AU - Ärnlöv, Johan
AU - Asayama, Kei
AU - Atkins, Robert
AU - Badawi, Alaa
AU - Ballew, Shoshana H.
AU - Banerjee, Amitava
AU - Barregård, Lars
AU - Barrett-Connor, Elizabeth
AU - Basu, Sanjay
AU - Bello, Aminu K.
AU - Bensenor, Isabela
AU - Bergstrom, Jaclyn
AU - Bikbov, Boris
AU - Blosser, Christopher
AU - Brenner, Hermann
AU - Carrero, Juan Jesus
AU - Chadban, Steve
AU - Cirillo, Massimo
AU - Cortinovis, Monica
AU - Courville, Karen
AU - Dandona, Lalit
AU - Dandona, Rakhi
AU - Estep, Kara
AU - Fernandes, João
AU - Fischer, Florian
AU - Fox, Caroline
AU - Gansevoort, Ron T.
AU - Gona, Philimon N.
AU - Gutierrez, Orlando M.
AU - Hamidi, Samer
AU - Hanson, Sarah Wulf
AU - Himmelfarb, Jonathan
AU - Jassal, Simerjot K.
AU - Jee, Sun Ha
AU - Jha, Vivekanand
AU - Jimenez-Corona, Aida
AU - Jonas, Jost B.
AU - Kengne, Andre Pascal
AU - Khader, Yousef
AU - Khang, Young Ho
AU - Kim, Yun Jin
AU - Klein, Barbara
AU - Klein, Ronald
AU - Kokubo, Yoshihiro
AU - Kolte, Dhaval
AU - Lee, Kristine
N1 - Publisher Copyright:
© 2017 by the American Society of Nephrology.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/7
Y1 - 2017/7
N2 - The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95%uncertainty interval [95%UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95%UI, 1.1 to 1.4million), whereas 0.96million (95%UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.
AB - The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95%uncertainty interval [95%UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95%UI, 1.1 to 1.4million), whereas 0.96million (95%UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.
UR - http://www.scopus.com/inward/record.url?scp=85021768228&partnerID=8YFLogxK
U2 - 10.1681/ASN.2016050562
DO - 10.1681/ASN.2016050562
M3 - Article
C2 - 28408440
AN - SCOPUS:85021768228
SN - 1046-6673
VL - 28
SP - 2167
EP - 2179
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 7
ER -